Tyrosine-protein kinase Fyn (Fyn) is a critical signaling molecule involved in various cellular processes, including neuronal development, synaptic plasticity, and disease pathogenesis. Dysregulation of Fyn kinase has been implicated in various complex diseases, including neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, as well as different cancer types. Therefore, identifying small molecule inhibitors that can inhibit Fyn activity holds substantial significance in drug discovery.
Objective:
The aim of this study was to identify potential small-molecule inhibitors among bioactive phytoconstituents against tyrosine-protein kinase Fyn.
Methods:
Through a comprehensive approach involving molecular docking, drug likeliness filters, and molecular dynamics (MD) simulations, we performed a virtual screening of a natural compounds library. This methodology aimed to pinpoint compounds potentially interacting with Fyn kinase and inhibiting its activity.
Results:
This study finds two potential natural compounds: Dehydromillettone and Tanshinone B. These compoundsdemonstrated substantial affinity and specific interactions towards the Fyn binding pocket. Their conformations exhibitedcompatibility and stability, indicating the formation of robust protein-ligand complexes. A significant array of non-covalentinteractions supported the structural integrity of these complexes.
Conclusion:
Dehydromillettone and Tanshinone B emerge as promising candidates, poised for further optimization as Fynkinase inhibitors with therapeutic applications. In a broader context, this study demonstrates the potential of computationaldrug discovery, underscoring its utility in identifying compounds with clinical significance. The identified inhibitors holdpromise in addressing a spectrum of cancer and neurodegenerative disorders. However, their efficacy and safety necessitatevalidation through subsequent experimental studies.
Warn-CramerBJ, LauAF (2004) Regulation of gap junctions by tyrosine protein kinases, Biochim Biophys Acta1662, 81–95.
2.
MannholdR, KubinyiH, FolkersG (2011) Protein Kinases as Drug Targets, John Wiley & Sons.
3.
SchenoneS, BrulloC, MusumeciF, BiavaM, FalchiF, BottaM (2011) Fyn kinase in brain diseases and cancer: The search for inhibitors, Curr Med Chem18, 2921–2942.
4.
MatroneC, PetrilloF, NassoR, FerrettiG (2020) Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions, Int J Mol Sci21, 4444.
EliasD, DitzelHJ (2015) Fyn is an important molecule in cancer pathogenesis and drug resistance, Pharm Res100, 250–254.
7.
LamersMB, AntsonAA, HubbardRE, ScottRK, WilliamsDH (1999) Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine, J Mol Biol285, 713–725.
8.
KinoshitaT, MatsubaraM, IshiguroH, OkitaK, TadaT (2006) Structure of human Fyn kinase domain complexed with staurosporine, Biochem Biophy Res Comm346, 840–844.
9.
SaitoYD, JensenAR, SalgiaR, PosadasEM (2010) Fyn: A novel molecular target in cancer, Cancer116, 1629–1637.
10.
PengS, FuY (2023) FYN: Emerging biological roles and potential therapeutic targets in cancer, J Translat Med21, 84.
11.
PoliG, TuccinardiT, RizzolioF, CaligiuriI, BottaL, GranchiC, OrtoreG, MinutoloF, SchenoneS, MartinelliA (2013) Identification of new Fyn kinase inhibitors using a FLAP-based approach, J Chem Infor Mod53, 2538–2547.
12.
MarottaG, BasagniF, RosiniM, MinariniA (2022) Role of Fyn kinase inhibitors in switching neuroinflammatory pathways, Curr Medi Chem29, 4738–4755.
13.
MorisotN, BergerAL, PhamluongK, CrossA, RonD (2019) The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking, Addict Biol24, 1227–1234.
14.
AtanasovAG, ZotchevSB, DirschVM, SupuranCT (2021) Natural products in drug discovery: Advances and opportunities, Nat Rev Drug Dis20, 200–216.
EgbunaC, KumarS, IfemejeJC, EzzatSM, KaliyaperumalS (2019) Phytochemicals as lead compounds for new drug discovery, Elsevier.
17.
ChoudhariAS, MandavePC, DeshpandeM, RanjekarP, PrakashO (2020) Phytochemicals in cancer treatment: From preclinical studies to clinical practice, Front Pharm10, 1614.
18.
AhmadSS, WaheedT, RozeenS, MahmoodS, KamalMA (2019) Therapeutic study of phytochemicals against cancer and Alzheimer’s disease management, Curr Drug Metab20, 1006–1013.
19.
vanHilten N, ChevillardF, KolbP (2019) Virtual compound libraries in computer-assisted drug discovery, J Chem Infor Mod59, 644–651.
20.
AndricopuloAD, GuidoRV, OlivaG (2008) Virtual screening and its integration with modern drug design technologies, Curr Med Chem15, 37–46.
21.
AmirM, MohammadT, PrasadK, HasanGM, KumarV, DohareR, IslamA, AhmadF, ImtaiyazHassan M (2020) Virtual high-throughput screening of natural compounds in-search of potential inhibitors for protection of telomeres 1 (POT1), J Biomol Str Dyn38, 4625–4634.
22.
MohammadT, SiddiquiS, ShamsiA, AlajmiMF, HussainA, IslamA, AhmadF, HassanMI (2020) Virtual screening approach to identify high-affinity inhibitors of serum and glucocorticoid-regulated kinase 1 among bioactive natural products: Combined molecular docking and simulation studies, Molecules25, 823.
23.
VaradiM, AnyangoS, DeshpandeM, NairS, NatassiaC, YordanovaG, YuanD, StroeO, WoodG, LaydonA (2022) AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. D439-D, Nucl Acids Res50, 444.
24.
Vivek-AnanthR, MohanrajK, SahooAK, SamalA (2023) IMPPAT 2.0: An enhanced and expanded phytochemical atlas of Indian medicinal plants, ACS Omega8, 8827–8845.
25.
DainaA, MichielinO, ZoeteV (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci Rep7, 42717.
26.
PiresDE, BlundellTL, AscherDB (2015) pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, J Med Chem58, 4066–4072.
27.
LipinskiCA (2004) Lead-and drug-like compounds: The rule-of-five revolution, Drug Dis Today Technol1, 337–341.
28.
BaellJB, NissinkJWM (2018) Seven year itch: Pan-Assay Interference Compounds (PAINS) in 2017-utility and limitations, ACS Chem Biol13, 36–44.
29.
TrottO, OlsonAJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comp Chem31, 455–461.
30.
KontoyianniM, McClellanLM, SokolGS (2004) Evaluation of docking performance: Comparative data on docking algorithms, J Comp Chem47, 558–565.
31.
AlbuquerqueSO, BarrosTG, DiasLR, LimaCHdS, PedroHdA, Flores-JuniorLA, Dos SantosEG, LoponteHF, PinheiroS, DiasWB (2020) Biological evaluation and molecular modeling of peptidomimetic compounds as inhibitors for O-GlcNAc transferase (OGT), Eur J Pharm Sci154, 105510.
32.
DeLanoWL (2002) Pymol: An open-source molecular graphics tool, CCP4 Newsl Protein Crystallogr40, 82–92.
Van Der SpoelD, LindahlE, HessB, GroenhofG, MarkAE, BerendsenHJ (2005) GROMACS: Fast, flexible, and free, J Comp Chem26, 1701–1718.
35.
de SouzaAS, PachecoBD, PinheiroS, MuriEM, DiasLR, LimaCH, GarrettR, de MoraesMB, de SouzaBE, PuzerL (2019) 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7, Bioorg Med Chem Lett29, 1094–1098.
36.
ElhadySS, AbdelhameedRF, MalataniRT, AlahdalAM, BogariHA, AlmalkiAJ, MohammadKA, AhmedSA, KhedrAI, DarwishKM (2021) Molecular docking and dynamics simulation study of hyrtios erectus isolated scalarane sesterterpenes as potential SARS-CoV-2 dual target inhibitors, Biology10, 389.
37.
HueyR, MorrisGM, ForliS (2012) Using AutoDock 4 and AutoDock vina with AutoDockTools: A tutorial, The Scripps Research Institute Molecular Graphics Laboratory10550, 92037.
38.
El-NaggarAM, HassanA, ElkaeedEB, AlesawyMS, Al-KarmalawyAA (2022) Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2, Bioorg Chem123, 105770.
39.
LaguninA, StepanchikovaA, FilimonovD, PoroikovV (2000) PASS: Prediction of activity spectra for biologically active substances, Bioinformatics16, 747–748.
40.
MaldeAK, ZuoL, BreezeM, StroetM, PogerD, NairPC, OostenbrinkC, MarkAE (2011) An automated force field topology builder (ATB) and repository: Version 1.0, J Chem Theory Comput7, 4026–4037.
41.
SchmidN, EichenbergerAP, ChoutkoA, RinikerS, WingerM, MarkAE, VanGunsteren WF (2011) Definition and testing of the GROMOS force-field versions 54A7 and 54B7, Eur Biophy J40, 843–856.
42.
WuY, TepperHL, VothGA (2006) Flexible simple point-charge water model with improved liquid-state properties, J Chem Phys124, 024503.
TurnerP (2005) XMGRACE, Version 5.1. 19. Center for Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology, Beaverton, OR, 2.
45.
KuhnB, GerberP, Schulz-GaschT, StahlM (2005) Validation and use of the MM-PBSA approach for drug discovery, J Med Chem48, 4040–4048.
46.
KumariR, KumarR; Open Source Drug Discovery Consortium; Lynn A (2014) g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations, J Med Chem Mod54, 1951–1962.
47.
DavidCC, JacobsDJ (2014) Principal component analysis: A method for determining the essential dynamics of proteins, Methods Mol Biol1084, 193–226.
48.
PapaleoE, MereghettiP, FantucciP, GrandoriR, De GioiaL (2009) Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: The myoglobin case, J Med Chem Mod27, 889–899.
49.
HodgsonJ (2001) ADMET—turning chemicals into drugs, Nat Biotech19, 722–726.
50.
PoliG, LapilloM, GranchiC, CaciollaJ, MouawadN, CaligiuriI, RizzolioF, LangerT, MinutoloF, TuccinardiT (2018) Binding investigation and preliminary optimisation of the 3-amino-1, 2, 4-triazin-5 (2 H)-one core for the development of new Fyn inhibitors, J Enz Inh Med Chem33, 956–961.
51.
HanksSK, HunterT (1995) The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification 1, FASEB J9, 576–596.
52.
NaqviAA, MohammadT, HasanGM, HassanM (2018) Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships, Curr Topics Med Chem18, 1755–1768.
53.
PandiniA, ForniliA, KleinjungJ (2010) Structural alphabets derived from attractors in conformational space, BMC Bioinformatics11, 97.
54.
PiteraJW (2014) Expected distributions of root-mean-square positional deviations in proteins, J Phys Chem B118, 6526–6530.
55.
AtilganC, GerekZ, OzkanS, AtilganA (2010) Manipulation of conformational change in proteins by single-residue perturbations, Biophys J99, 933–943.
56.
LobanovMY, BogatyrevaN, GalzitskayaO (2008) Radius of gyration as an indicator of protein structure compactness, Mol Biol42, 623–628.
57.
MarshJA, TeichmannSA (2011) Relative solvent accessible surface area predicts protein conformational changes upon binding, Structure19, 859–867.
PaceCN, FuH, LeeFryar K, LanduaJ, TrevinoSR, SchellD, ThurlkillRL, ImuraS, ScholtzJM, GajiwalaK (2014) Contribution of hydrogen bonds to protein stability, Prot Sci23, 652–661.
60.
Farías-RicoJA, SchmidtS, HöckerB (2014) Evolutionary relationship of two ancient protein superfolds, Nat Chem Biol10, 710–715.
61.
UverskyV (2003) Protein folding revisited. A polypeptide chain at the folding–misfolding–nonfolding cross-roads: Which way to go?Cell Mol Life Sci60, 1852–1871.
62.
Č alićM, JelićD, AntolovićR, NujićK, MarjanovićN, Stupin PolančecD, Vikić-TopićS, VerbanacD (2005) Flavonoids as inhibitors of Lck and Fyn kinases, Croat Chem Acta78, 367–374.
63.
BaierA, SzyszkaR (2020) Compounds from natural sources as protein kinase inhibitors, Biomolecules10, 1546.
64.
LuY, CaiS, NieJ, LiY, ShiG, HaoJ, FuW, TanH, ChenS, LiB (2016) The natural compound nujiangexanthone A suppresses mast cell activation and allergic asthma, Biochem Pharmacol100, 61–72.
65.
KWL (2008) Raf and MEK protein kinase are direct molecular targets for the chemopreventive effects of quercetin, a major flavonol in red wine, Cancer Res68, 3–24.
66.
KangNJ, LeeKW, ShinBJ, JungSK, HwangMK, BodeAM, HeoY-S, LeeHJ, DongZ (2009) Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression, Carcinogenesis30, 321–330.
